These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 14676630)
1. Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapy. Ciavarra RP; Holterman DA; Brown RR; Mangiotti P; Yousefieh N; Wright GL; Schellhammer PF; Glass WF; Somers KD J Immunother; 2004; 27(1):13-26. PubMed ID: 14676630 [TBL] [Abstract][Full Text] [Related]
2. Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer. Ciavarra RP; Brown RR; Holterman DA; Garrett M; Glass WF; Wright GL; Schellhammer PF; Somers KD Cancer Immunol Immunother; 2003 Sep; 52(9):535-45. PubMed ID: 14627125 [TBL] [Abstract][Full Text] [Related]
3. Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: efficacy of flt3 ligand immunotherapy. Somers KD; Brown RR; Holterman DA; Yousefieh N; Glass WF; Wright GL; Schellhammer PF; Qian J; Ciavarra RP Int J Cancer; 2003 Dec; 107(5):773-80. PubMed ID: 14566827 [TBL] [Abstract][Full Text] [Related]
4. Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer. Ciavarra RP; Somers KD; Brown RR; Glass WF; Consolvo PJ; Wright GL; Schellhammer PF Cancer Res; 2000 Apr; 60(8):2081-4. PubMed ID: 10786663 [TBL] [Abstract][Full Text] [Related]
5. Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. Shafer-Weaver KA; Watkins SK; Anderson MJ; Draper LJ; Malyguine A; Alvord WG; Greenberg NM; Hurwitz AA Cancer Res; 2009 Aug; 69(15):6256-64. PubMed ID: 19622771 [TBL] [Abstract][Full Text] [Related]
6. Flt3 ligand expands dendritic cell numbers in normal and malignant murine prostate. Moghaddami M; Swart B; Reynolds P; Diener K; Brown MP Immunol Cell Biol; 2002 Aug; 80(4):370-81. PubMed ID: 12121227 [TBL] [Abstract][Full Text] [Related]
7. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity. Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082 [TBL] [Abstract][Full Text] [Related]
8. CD40 ligand promotes priming of fully potent antitumor CD4(+) T cells in draining lymph nodes in the presence of apoptotic tumor cells. Fujita N; Kagamu H; Yoshizawa H; Itoh K; Kuriyama H; Matsumoto N; Ishiguro T; Tanaka J; Suzuki E; Hamada H; Gejyo F J Immunol; 2001 Nov; 167(10):5678-88. PubMed ID: 11698440 [TBL] [Abstract][Full Text] [Related]
9. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells. Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078 [TBL] [Abstract][Full Text] [Related]
10. Combinational FLt3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy. Berhanu A; Huang J; Alber SM; Watkins SC; Storkus WJ Cancer Res; 2006 May; 66(9):4895-903. PubMed ID: 16651446 [TBL] [Abstract][Full Text] [Related]
11. Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer. Liu Z; Eltoum IE; Guo B; Beck BH; Cloud GA; Lopez RD J Immunol; 2008 May; 180(9):6044-53. PubMed ID: 18424725 [TBL] [Abstract][Full Text] [Related]
12. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model. Mineharu Y; Muhammad AK; Yagiz K; Candolfi M; Kroeger KM; Xiong W; Puntel M; Liu C; Levy E; Lugo C; Kocharian A; Allison JP; Curran MA; Lowenstein PR; Castro MG Neurotherapeutics; 2012 Oct; 9(4):827-43. PubMed ID: 22996231 [TBL] [Abstract][Full Text] [Related]
13. Dendritic cells in models of tumor immunity. Role of Flt3 ligand. Maliszewski C Pathol Biol (Paris); 2001 Jul; 49(6):481-3. PubMed ID: 11484609 [TBL] [Abstract][Full Text] [Related]
14. Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer. Riabov V; Tretyakova I; Alexander RB; Pushko P; Klyushnenkova EN Vaccine; 2015 Oct; 33(41):5386-5395. PubMed ID: 26319744 [TBL] [Abstract][Full Text] [Related]
15. Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes. Peek EM; Song W; Zhang H; Huang J; Chin AI Prostate; 2015 Apr; 75(5):463-73. PubMed ID: 25597486 [TBL] [Abstract][Full Text] [Related]
16. An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 2. Tumor-specific immunity and cure after radio-inducible suicide gene therapy and systemic CD40-ligand and Flt3-ligand gene therapy in an orthotopic tumor model. Kawashita Y; Deb NJ; Garg MK; Kabarriti R; Fan Z; Alfieri AA; Roy-Chowdhury J; Guha C Radiat Res; 2014 Aug; 182(2):201-10. PubMed ID: 24992166 [TBL] [Abstract][Full Text] [Related]
17. Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model. Dzojic H; Loskog A; Tötterman TH; Essand M Prostate; 2006 Jun; 66(8):831-8. PubMed ID: 16491482 [TBL] [Abstract][Full Text] [Related]
18. Fms-Like Tyrosine Kinase 3-Ligand Contributes to the Development and Function of the Subpopulation of CD8α Huang Y; Xu H; Miller T; Wen Y; Ildstad ST Stem Cells; 2018 Oct; 36(10):1567-1577. PubMed ID: 30004616 [TBL] [Abstract][Full Text] [Related]
19. NK cells mediate Flt3 ligand-induced protection of dendritic cell precursors in vivo from the inhibition by prostate carcinoma in the murine bone marrow metastasis model. Tourkova IL; Yamabe K; Chatta G; Shurin GV; Shurin MR J Immunother; 2003; 26(6):468-72. PubMed ID: 14595214 [TBL] [Abstract][Full Text] [Related]
20. Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival. Lu L; Li W; Fu F; Chambers FG; Qian S; Fung JJ; Thomson AW Transplantation; 1997 Dec; 64(12):1808-15. PubMed ID: 9422424 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]